Chronic kidney disease and hyperuricemia: mechanisms of development and clinical manifestations

Abstract

Hyperuricemiaand gout are diseases that threaten the lives of patients with their cardiovascular complications and the development of chronic kidney disease (CKD). Continuous monitoring of uric acid (MC) levels below 360 μmol/l reduces the number of gout attacks and prevents the development of delayed complications. Timely prescribed and correctly selected hypouricemic therapy contributes to the normalization of metabolic processes, in the glomerular filtration rate (GFR) and the level of albumin excretion, and eliminates the risk factors for the progression of CKD. Febuxostat (Adenuric) ensures the rapid achievement of the target MC numbers and subsequent tight control. It is three times more effective than allopurinol in controlling target uric acid levels, provides a reverse regression of deposited uric acid, and does not require dose adjustment for elderly patients with impaired renal function. This drug is significantly more effective than allopurinol at initially high levels of uric acid, in addition, it has significantly fewer side effects due to the selective blockade of xanthine oxidase.